<div id="readability-page-1"><p>In a report released on December 16, William Plovanic from Canaccord Genuity maintained a Buy rating on Neuronetics, with a price target of <span id="expert-recommendation-target">$7.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Plovanic is a 4-star analyst with an average return of <span>4.5%</span> and a 45.49% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Edwards Lifesciences.</p> <p>Neuronetics has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.</p></div>

STIM

<p>Canaccord Genuity's William Plovanic maintains a Buy rating on Neuronetics (STIM) with a $7.00 price target. Plovanic, a 4-star analyst with a 4.5% average return, focuses on the Healthcare sector. Neuronetics has a Moderate Buy consensus and a $7.00 price target consensus.</p>

Canaccord Genuity Keeps Their Buy Rating on Neuronetics (STIM)